12:00 AM
 | 
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Revlimid lenalidomide regulatory update

The National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines for multiple myeloma (MM) to include a category 1 recommendation for Celgene's Revlimid lenalidomide for the maintenance treatment of MM. Revlimid previously had a category 2A recommendation for the indication. According to NCCN, a category 1 recommendation means that...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >